Relay Therapeutics is trading 4.1% down at $17.21, with no confirmed company-specific announcement explaining the October 8 decline. - Available coverage likewise reported no company-specific news behind the prior session’s drop. - Biotech ETF XBI is down 2.04%; rising oil prices, inflation concerns and elevated bond yields are weighing on markets. These provide sector and macro context, but no verified report directly attributes the decline to a specific catalyst.